Shots:

• The P-III IMpower130 study involves assessing of Tecentriq (atezolizumab) + CT (carboplatin and nab-paclitaxel) vs CT (carboplatin and nab-paclitaxel) in ratio (2:1) in 723 patients with stage IV non-sq NSCLC in ITT-WT population
• P-III IMpower130 study results: mOS (18.6 vs 13.9); ORR (49.2% vs 31.9%); mDOR (8.4 vs 6.1 mos.); mPFS (7.0 vs 5.5 mos.). Presented at ESMO'18
• Tecentriq is a mAb used for binding PD-L1 protein & is currently approved in 70 countries including the US and EU. Additionally- Roche has eight P-III lung cancer studies evaluating Tecentriq alone or + other drugs

Ref: Roche | Image: Roche